Fosphenytoin Dosing
For status epilepticus, administer fosphenytoin at a loading dose of 15-20 mg PE/kg IV, with adults receiving 100-150 mg PE/min (maximum 150 mg PE/min) and children receiving 2 mg PE/kg/min (or 150 mg PE/min, whichever is slower). 1
Loading Doses by Clinical Scenario
Status Epilepticus (Emergency)
Adults:
- Dose: 15-20 mg PE/kg IV
- Infusion rate: 100-150 mg PE/min (do not exceed 150 mg PE/min)
- Maximum single dose: Typically 1000-1500 mg total 1
Pediatrics (birth to <17 years):
- Dose: 15-20 mg PE/kg IV 2, 1
- Infusion rate: 2 mg PE/kg/min OR 150 mg PE/min, whichever is slower 1
- Maximum initial dose: 1000 mg 2
- Neonates: 10 mg PE/kg (phenobarbital preferred due to decreased protein binding) 2
Critical caveat: IM administration should ordinarily NOT be used for status epilepticus because therapeutic concentrations are not reached as quickly as IV 1. The full antiepileptic effect is not immediate—concomitant IV benzodiazepine is usually necessary 1.
Non-Emergent Loading
Adults:
- Dose: 10-20 mg PE/kg IV
- Infusion rate: Maximum 150 mg PE/min 1
Pediatrics:
- Dose: 10-15 mg PE/kg IV
- Infusion rate: 1-2 mg PE/kg/min OR 150 mg PE/min, whichever is slower 1
Maintenance Dosing
Adults
- Initial maintenance: 4-6 mg PE/kg/day in divided doses
- Infusion rate: Maximum 150 mg PE/min 1
- Start maintenance dosing after the loading dose is complete
Pediatrics
- Initial maintenance dose: 2-4 mg PE/kg given 12 hours after loading dose
- Subsequent maintenance: 4-8 mg PE/kg/day in divided doses (every 12 hours)
- Infusion rate: 1-2 mg PE/kg/min OR 100 mg PE/min, whichever is slower 1
Important timing consideration: In pediatric patients, maintenance dosing should begin 12 hours after the loading dose rather than 24 hours, with dosing every 12 hours providing better therapeutic control than every 24 hours 3.
Monitoring and Safety
When to Check Levels
- Do NOT check phenytoin levels until conversion is complete:
- 2 hours after IV infusion ends
- 4 hours after IM injection 1
- Optimal pediatric monitoring: Measure free phenytoin at 2 hours and 12 hours after loading dose 3
- Standard immunoassays (TDx, Emit) will overestimate concentrations before complete conversion due to cross-reactivity with fosphenytoin 1
Target Concentrations
- Total phenytoin: 10-20 mcg/mL
- Free (unbound) phenytoin: 1-2 mcg/mL 1
- Monitor free phenytoin in patients with renal disease, hepatic disease, or hypoalbuminemia 1
Essential Monitoring During Infusion
Continuous monitoring is mandatory throughout infusion and for 10-20 minutes after completion (when peak concentrations occur) 1:
- Continuous ECG
- Blood pressure
- Respiratory function
Common Pitfalls
Cardiovascular effects: While fosphenytoin has significantly lower risk of hypotension and cardiac arrhythmias compared to phenytoin 2, 4, hypotension can still occur, particularly at higher infusion rates 5. Reduce infusion rate if heart rate decreases by 10 beats per minute 2.
Overshoot phenomenon: Loading doses of 20 mg PE/kg frequently produce supratherapeutic free phenytoin levels immediately post-infusion (mean 17.7 mg/L in one study), though levels typically normalize to therapeutic range within 24 hours 6. In neonates and infants <6 months, both 15 and 20 mg PE/kg doses produce elevated free concentrations (average 2.45-2.52 mg/L) 7.
Efficacy limitations: Even with therapeutic levels achieved, seizure control rates are only 56-88% 5, 8. If seizures persist after fosphenytoin, consider alternative agents (valproate, levetiracetam, phenobarbital) 5.
IM administration: Should ordinarily NOT be used in pediatric patients 1. When IV access is impossible in adults, IM fosphenytoin is completely absorbed and well-tolerated, but therapeutic levels are delayed 9, 10.
Comparative Context
The 2014 ACEP guidelines note that fosphenytoin offers no efficacy advantage over phenytoin but has fewer adverse effects, particularly less soft-tissue injury and cardiovascular complications 5. The 2024 ESETT trial found no difference in efficacy between fosphenytoin (45% seizure cessation), levetiracetam (47%), and valproate (46%) for refractory status epilepticus 11. A 2020 propensity-matched study of 5,265 patients found no difference in vasopressor use, mechanical ventilation, or mortality between phenytoin and fosphenytoin 12.